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Abstract
Background: Recent changes to diagnostic criteria for depression in DSM-5 remove the bereavement exclusion, allowing
earlier diagnosis following bereavement. Evaluation of the potential effect of this change requires an understanding of
existing psychotropic medication prescribing by non-specialists after bereavement.
Aims: To describe initiation of psychotropic medication in the first year after partner bereavement.
Methods: In a UK primary care database, we identified 21,122 individuals aged 60 and over with partner bereavement and
no psychotropic drug use in the previous year. Prescribing (anxiolytic/hypnotic, antidepressant, antipsychotic) after
bereavement was compared to age, sex and practice matched controls.
Results: The risks of receiving a new psychotropic prescription within two and twelve months of bereavement were 9.5%
(95% CI 9.1 to 9.9%) and 17.9% (17.3 to 18.4%) respectively; an excess risk of initiation in the first year of 12.4% compared to
non-bereaved controls. Anxiolytic/hypnotic and antidepressant initiation rates were highest in the first two months. In this
period, the hazard ratio for initiation of anxiolytics/hypnotics was 16.7 (95% CI 14.7 to 18.9) and for antidepressants was 5.6
(4.7 to 6.7) compared to non-bereaved controls. 13.3% of those started on anxiolytics/hypnotics within two months
continued to receive this drug class at one year. The marked variation in background family practice prescribing of
anxiolytics/hypnotics was the strongest determinant of their initiation in the first two months after bereavement.
Conclusion: Almost one in five older people received a new psychotropic drug prescription in the year after bereavement.
The early increase and trend in antidepressant use after bereavement suggests some clinicians did not adhere to the
bereavement exclusion, with implications for its recent removal in DSM-5. Family practice variation in use of anxiolytics/
hypnotics suggests uncertainty over their role in bereavement with the potential for inappropriate long term use.
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Introduction
Bereavement and grief are near universal human experiences
which adversely impact on physical and psychological health [1].
Recent changes in diagnostic criteria for depression after
bereavement have highlighted a polarised debate over the role
of medical care in managing the psychological impact of
bereavement [2]. Existing criteria, also implemented in the UK,
limited a diagnosis of a major depressive disorder within two
months of bereavement to those with marked symptoms unchar-
acteristic of normal grief [3,4]. This bereavement exclusion was
intended to prevent over diagnosis of depression which may be
difficult to distinguish from normal grief; a self-limiting process for
the majority [3,4]. The change to the Diagnostic and Statistical
Manual of Mental Disorders (DSM) allows a diagnosis of
depression at any time after bereavement, based on standard
depression criteria, but maintains the position that acute grief is
not a mental disorder [4].
Although current discussion has focussed on depression, the
appropriateness of anxiolytic/hypnotic prescribing after bereave-
ment has also been questioned, with concern over long-term use
and blunting of normal grief responses [5,6]. Despite this, there is
limited information on current prescribing practice for unselected
bereaved individuals [7,8]. Specifically, it is not known whether
the bereavement exclusion was followed for antidepressant
prescribing and whether hypnotic use is appropriately time-
limited. This information is important as the current debate over
changes to DSM-5 is based on detailed assessment of psychological
symptoms after bereavement and specialist assessment, whilst the
majority of prescribing after bereavement in many countries, such
as the UK, is undertaken in primary care. It is likely that the
circumstances and specificity of diagnostic decisions will be
different in primary care, which will mean that the consequences
of changes in depression criteria may not be predictable. Recent
studies have reported increased use of psychotropic medication
after bereavement but have not directly examined the pattern of
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initiation of specific drug classes in relation to current guidance
[7,8]. This is a key gap in the evidence base to help understand the
practical implications of changes in diagnostic criteria.
In this study, we describe initiation, continuation and determi-
nants of psychotropic medication prescribing in the first year after
partner bereavement in a large primary care based sample of older
people in the United Kingdom. Specifically, we examine whether
antidepressant prescribing was limited by primary care physicians
in the first two months after bereavement, as an indicator of
adherence to the existing bereavement exclusion, and whether
prescribing of anxiolytics/hypnotics after bereavement leads to
long-term use.
Methods
Data Source
The Health Improvement Network (THIN) is an established
primary care database which collects anonymised data from UK
general practices and includes a full record of diagnoses and
prescribing [9,10]. The THIN database includes approximately
6% of the UK population. A feature of the THIN database is the
family number which allows practices to identify patients who live
in the same household [11].
Ethics Statement
The National Health Service South East Multicentre Research
Ethical Committee approved the THIN scheme to collect
anonymous patient data in 2002. This approval allows collection
of anonymised patient data for research use without individual
patient consent but allows patients to opt out of the scheme. This
specific study was further approved by the South-East NHS
Research Ethics Committee (11/H1102/3).
Subjects
Out of 495 practices providing data to the THIN scheme at
study inception in 2010, we included all 401 practices active in
THIN scheme between 2005 and 2008 which were able to provide
data for at least one year. We used a historical patient file to
identify the household composition for a cohort of older patients
aged 60 and over on a specified (index) date between 2005 and
2008 for each practice (n = 672,543).
We developed an algorithm, described in detail elsewhere, to
identify 171,720 couples with an age difference of ten years or less
[12]. We have confirmed the validity of our algorithm by
comparison with national representative surveys in England which
confirm that 99.4% of couples selected using our criteria identify
themselves as married or cohabiting [12].
Bereavement
Couples were followed in the primary care record from the
index date for their practice to their last practice data collection
date up to September 2011. The timing of bereavement was
identified through the record of death in the deceased partner’s
primary care record. 31,370 older people experienced bereave-
ment during follow up and our analysis is restricted to 29,548 aged
between 60 and 89 at beginning of follow up.
Psychotropic Drug Prescribing
We identified any prescription for anxiolytics, hypnotics,
antidepressants and antipsychotics in the primary care record.
Low dose amitriptyline (,50 mg) prescribing was examined
separately and not included in our main antidepressant or
composite psychotropic drug group. In the UK, low dose
amitriptyline may be prescribed for pain management or as a
hypnotic. We defined initiation as a new prescription of any of
these drug classes in a bereaved individual who had not received
any psychotropic medication in the year before bereavement.
Study Design
Our main design was a matched cohort study which compared
rates of prescribing in bereaved individuals to those in an age, sex,
practice and period matched cohort. This allowed description of
cumulative, relative, and absolute differences in initiation of
prescribing in the first year after bereavement compared to non-
bereaved individuals. Our main analysis is focused on bereaved
individuals and matched controls who were not in receipt of any
psychotropic drugs in the year before bereavement. This allows a
description of the direct effect of bereavement on initiation of
medication.
Matched Control Groups
Two distinct control groups of non-bereaved individuals were
identified who were registered on the bereavement date of their
matched counterpart with matching on age (in five year age
bands), sex and practice. The first group matched all bereaved
individuals and was used for preliminary description of prescribing
patterns before and after bereavement. The second group
matched bereaved individuals who had not received psychotropic
medication in the year before bereavement to controls who had
also not received psychotropic medication. This second group was
used for our main analysis of medication initiation after
bereavement. Up to three controls were matched for every
bereaved individual.
Participants
Of the 29,548 bereaved individuals aged 60 to 89 at baseline,
21,668 (73%) had not received a prescription of any psychotropic
medication in the year before bereavement. For our first matched
groups, 28,800 (97.5%) of all bereaved individuals were success-
fully matched with at least one non-bereaved control giving 80,471
age, sex and practice matched non-bereaved controls For our
second matched group, 21,122 (97.5%) of bereaved individuals
free of psychotropic medication in the year before bereavement
were successfully matched with at least one non-bereaved control
who was also free of psychotropic medication a year before the
bereavement date, giving 59,280 age, sex and practice matched
non-bereaved controls. All analyses only include bereaved
individuals with at least one matched control.
Analysis
Initial graphical analysis of prescribing patterns, before and
after bereavement, identified the proportion of patients still
registered that had received a prescription in the last month (30
days). Descriptive analysis presents Kaplan-Meier estimates of the
probability of bereaved individuals receiving a new first prescrip-
tion of each class of drug in the two (60 days), six (180 days) and
twelve (365 days) months after bereavement with individuals
censored from the analysis on death or deregistration.
Subsequent analysis compared initiation rates in consecutive
periods (0–2 months, 2–6 months and 6–12 months) in the first
year after bereavement for bereaved individuals and the matched
control group. Hazard ratios for initiation are based on a Cox
proportional hazards survival model, stratified by matched sets.
Continuation
Continuation of prescribing at the first anniversary of bereave-
ment, among those initiated within two months (60 days), was
Psychotropic Medication after Bereavement
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Figure 1. Proportion of Patients in Receipt of Psychotropic Medication in the Year Before and After Bereavement. Blue: All Bereaved
(n = 29,548) Green: All Non-Bereaved (n = 80,471) Red: Bereaved without psychotropic medication in year before bereavement (n = 21,122) Purple:
Non-Bereaved without psychotropic medication in year before bereavement (n = 59,280) Daily percentages are based on a denominator of patients
still registered on that day.
doi:10.1371/journal.pone.0077734.g001
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defined as receipt of a prescription for the same drug class in the
last three months (90 days) of the year. We excluded patients who
had died or deregistered at one year. The mean number of
prescriptions of each drug class in the first year after bereavement
is also presented as an alternate measure of continuation.
Guidelines on use of anxiolytics and hypnotics suggest that they
should be time-limited for periods of two to four weeks while
antidepressant therapy is recommended for at least six months
after remission [13].
Predictors of Initiation
Predictors of initiation of anxiolytics/hypnotics, within two
months, and antidepressants within six months of bereavement
were examined and compared to predictors in non-bereaved
controls. The timeframe for anxiolytics/hypnotics was based on
the existing DSM-IV threshold for the acute grief period (2
months) and for antidepressants based on the proposed threshold
for diagnosis of complicated grief (after 6 months).
Our main measure of comorbidity was the Charlson Index, a
validated score that weights 17 chronic physical conditions with a
score of 1 to 6 [14]. The Townsend Index, a composite small area
ecological measure of deprivation, was assigned to couples based
on their postcode and summarised as quintiles based on national
ranking [15]. Season of bereavement was based on standard UK
definitions, with December to March defined as Winter [16].
Unexpected bereavements were defined as bereavements where
the deceased partner had no recorded Charlson comorbidity or
other disabling condition more than 30 days before their death
[17].
General practice prescribing characteristics were based on
background prescribing of anxiolytics/hypnotics or antidepres-
sants to non-bereaved couples in 2008. Practices were classified in
quintiles, from lowest to highest, based on the proportion of non-
bereaved individuals who received a prescription of the drug class
during the year.
Predictors of psychotropic drug initiation were examined using
a Cox proportional hazards model with separate models for
bereaved and non-bereaved individuals. Hazard ratios were
adjusted for clustering at practice level using the sandwich
estimator to produce robust standard errors. P values for an
interaction between bereavement status and individual predictors
were derived from a combined model including both bereaved
individuals and non-bereaved controls.
Results
Follow Up
Mean age at bereavement was 76.2 years (range 60–95). Among
the bereaved with no psychotropic medication use in the year
before bereavement, 16,113/21,122 (76.3%) contributed a full
year of post-bereavement follow up, 633 (3.0%) died within one
year, 789 (3.7%) left their practice in the first year and 3,587
(17.0%) were bereaved less than a year before end of follow up for
their practice. In the matched control group, 46,882/59,280
(79.1%) contributed a full year of follow up. Irrespective of follow
up time, 3,547/21,122 bereaved individuals and 2,907/59,280
controls received a new prescription of a psychotropic medication
in the first year after bereavement.
Pattern of Psychotropic Drug Prescribing
Figure 1 shows the temporal pattern of medication use before
and after bereavement in (i) all bereaved individuals and (ii) those
without any prescription in the year before bereavement
(initiation), with their respective matched control group. For all
medication, bereaved individuals experienced higher prescribing
before bereavement (figure 1a). After bereavement, there was a
sharp rise in all prescribing in the first two months followed by
decline but levels remained persistently elevated throughout the
first year compared to both the control group and pre-
bereavement prescribing. This overall pattern largely reflects
anxiolytic/hypnotic prescribing (figure 1b). Antidepressant pre-
scribing exhibited a slower rise in the first two months and a more
persistent increase over the first year after bereavement (figure 1c).
Initiation of Psychotropic Medication
The probability of initiation of medications during the first year
after bereavement is shown in figure 2. 9.5% (95% CI 9.1 to 9.9%)
of bereaved individuals were newly prescribed any psychotropic
medication in the two months after bereavement and 17.9% (17.3
to 18.4%) within a year of bereavement. This compares to 0.9%
(0.8 to 1.0%) and 5.4% (5.3 to 5.6%) for the non-bereaved
controls. This is an absolute difference in the probability of
initiation of 8.6% in the first two months and 12.4% at one year
between the bereaved and non-bereaved groups.
Figure 2. Probability of Initiation (%) of Psychotropic Drugs in
the Year after Bereavement in Bereaved (B) and Non Bereaved
(NB) Patients. Initiation probabilities during the first year after
bereavement are derived from Kaplan Meier estimates and divided
into the following periods Light Grey: 6–12 months Medium Grey: 2–6
months Dark Grey: 0–2 months.
doi:10.1371/journal.pone.0077734.g002
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Among the bereaved, the risks of receiving a new prescription of
anxiolytics/hypnotics and antidepressants in the first two months
were 8.3% (8.0 to 8.7%) and 1.8% (1.6 to 1.9%) respectively
compared to 0.6% (0.5 to 0.6%) and 0.3% (0.3 to 0.4%) of non-
bereaved controls (figure 2). In the two months after bereavement,
the most common first prescribed medications were Zopiclone
(31%), Diazepam (26%) and Temazepam (22%).
Matched Comparison
Further analysis confirmed the elevated initiation rates through-
out the first year for all classes of psychotropic drugs (table 1). In
matched analysis, compared to the non-bereaved controls, the
increased absolute and relative risk of receiving a prescription was
most marked in the first two months for anxiolytics/hypnotics
(absolute rate difference (ARD) 3.92% per month, HR 16?7) and
antidepressants (ARD 0.7% per month, HR 5?6). This effect
persisted for antidepressants between two and six months (ARD
0.64% per month, HR 4?3) but attenuated between six and twelve
months (ARD 0.29% per month, HR 2?5). The trend in both
absolute and relative excess rate of antidepressant prescribing
showed the greatest increase in the first two months of prescribing,
the period of the bereavement exclusion. Analysis restricted to
patients with a full year of follow up gave the same findings.
The pattern of low dose amitriptyline use after bereavement was
different from other antidepressants with a less marked rise.
Similarly, antipsychotic prescribing showed a very small absolute
increase after bereavement. Further adjustment of hazard ratios
for deprivation and comorbidity made no difference to our
findings for any prescribing outcome.
Continuation
Overall, 25.2% (395/1566) who started a psychotropic medi-
cation within two months were receiving some psychotropic
medication at one year (table 2). 13.3% (185/1392) continued to
receive anxiolytics/hypnotics, with an average of 2.55 prescrip-
tions per patient, and 43.9% (123/280) continued to receive
antidepressants. Continuation was similar in bereaved and non-
bereaved individuals.
Predictors of Initiation
Predictors of initiation of anxiolytics/hypnotics in the first two
months are shown for bereaved individuals in table 3. Anxiolytic/
hypnotic prescribing was slightly more common in women and
lower in older individuals but deprivation or comorbidity had little
influence on prescribing. This contrasts with prescribing in the
non-bereaved where comorbidity was a strong predictor and
prescribing increased with age. Practice background prescribing
was the strongest independent predictor of initiation with a hazard
ratio of 1.70 (95% CI 1.43 to 2.03) for bereaved individuals in the
highest quintile practices compared to those in the lowest
prescribing quintile. Absolute Initiation after bereavement was
Table 1. Psychotropic Medication Initiation in the First Year after Bereavement Compared to Non-Bereaved Patients.
Drug
Group
Time after
bereavement
Bereaved
(n=21,122)
Non-Bereaved
(n =59,280) Bereaved (n=21,122) vs. Non-Bereaved (n=59,280)
Number
initiating
Initiation
Rate/100
PMARa
Number
initiating
Initiation
Rate/100
PMARa
Absolute
difference/100
PMARa 95% CI
Hazard
Ratio 95% CI
Anxiolytics/
Hypnotics
0–2 months 1744 4.20 329 0.28 +3.92 3.72 to 4.12 16.68 14.73 to 18.88
2–6 months 488 0.68 634 0.29 +0.40 0.33 to 0.46 2.45 2.16 to 2.76
6–12 months 336 0.35 887 0.29 +0.06 0.02 to 0.10 1.21 1.06 to 1.38
0–12 months 2,568 1.12 1,850 0.28 +0.84 0.79 to 0.88 4.50 4.22 to 4.79
Antidepressantsb 0–2 months 361 0.87 181 0.15 +0.72 0.62 to 0.81 5.58 4.65 to 6.70
2–6 months 635 0.83 422 0.19 +0.64 0.57 to 0.70 4.29 3.78 to 4.87
6–12 months 489 0.48 585 0.19 +0.29 0.24 to 0.33 2.53 2.23 to 2.87
0–12 months 1,485 0.65 1,188 0.18 +0.47 0.43 to 0.50 3.66 3.38 to 3.96
Low Dose
Amitriptyline only
0–2 months 162 0.39 200 0.17 +0.22 0.15 to 0.28 2.36 1.92 to 2.92
2–6 months 237 0.31 437 0.20 +0.11 0.07 to 0.15 1.59 1.35 to 1.86
6–12 months 253 0.24 624 0.20 +0.04 0.00 to 0.07 1.15 0.99 to 1.33
0–12 months 652 0.29 1,261 0.19 +0.09 0.07 to 0.12 1.49 1.36 to 1.65
Antipsychotics 0–2 months 33 0.08 39 0.03 +0.05 0.02 to 0.08 2.09 1.30 to 3.36
2–6 months 53 0.07 104 0.05 +0.02 0.00 to 0.04 1.42 1.01 to 1.99
6–12 months 59 0.05 133 0.04 +0.01 20.01 to 0.03 1.23 0.90 to 1.68
0–12 months 145 0.06 276 0.04 +0.02 0.00 to 0.03 1.43 1.16 to 1.76
All Psychotropicsb 0–2 months 1978 4.76 526 0.45 +4.31 4.10 to 4.52 11.82 10.68 to 13.08
2–6 months 915 1.29 1024 0.46 +0.83 0.74 to 0.92 2.77 2.52 to 3.04
6–12 months 654 0.71 1357 0.45 +0.26 0.20 to 0.32 1.58 1.43 to 1.74
0–12 months 3,547 1.54 2,907 0.45 +1.10 1.04 to 1.15 3.96 3.76 to 4.17
aPerson months at risk (% Initiation per month).
bExcludes low dose amitriptyline.
doi:10.1371/journal.pone.0077734.t001
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markedly higher in practices with high background prescribing;
11.2% in practices in the highest quintile compared to 6.2% in
those in the lowest quintile.
For initiation of antidepressants in the first six months (table 4),
female gender, comorbidity, deprivation and a history of
depression predicted prescribing but age had no clear trend. In
the non-bereaved, determinants of prescribing were similar except
that increasing age increased the likelihood of prescribing and
deprivation was a stronger predictor. Background practice
prescribing of antidepressants strongly influenced antidepressant
prescribing after bereavement. For both classes of drugs,
unexpected bereavement did not strongly influence the likelihood
of receiving medication.
Discussion
We have identified a marked increase in initiation of both
anxiolytics and antidepressants after bereavement with almost one
in five older people receiving a new psychotropic medication in the
first year after death of their partner. For antidepressants,
comparison of prescribing in the first two months after bereave-
ment to subsequent months, suggests that clinicians do not adhere
to the bereavement exclusion. For both anxiolytics/hypnotics and
antidepressants, the likelihood of prescribing after bereavement is
strongly determined by practice prescribing propensity and, for
anxiolytics/hypnotics, subsequent long-term use is not uncom-
mon.
Strengths and Weaknesses
Our study describes prescribing in a large unselected commu-
nity based population across the United Kingdom. Our matched
analysis allows direct comparison between bereaved and non-
bereaved individuals taking account of practice variation and
temporal trends.
We restricted our main analysis to individuals who were free of
any psychotropic prescribing in the year before bereavement to
exclude individuals with pre-bereavement psychological problems
which may worsen after bereavement. This means that our
estimates of initiation after bereavement are conservative as
individuals receiving one class of psychotropic drug were more
likely to start another type after bereavement.
For depression, we have chosen to report on prescribing
outcomes rather than recorded depression diagnoses. We believe
that this approach is preferable as it avoids concerns over
variations in diagnostic recording and coding between clinicians,
especially if these are related to knowledge of a recent
bereavement. We cannot exclude the possibility that patients
receiving antidepressants in the first two months after bereavement
met the stringent diagnostic criteria with marked functional
impairment or severe symptoms required in DSM-IV but this is
unlikely. Crucially, the fall in antidepressant prescribing in the
next four month period is inconsistent with this explanation.
Our analysis does not take account of receipt of psychological
therapy either before or after bereavement. Uptake of this
intervention is not as consistently recorded as prescribing and
the main focus of our paper was psychotropic drug use. It is
possible that differential use of psychological therapies could
explain some of the differences between bereaved and non-
bereaved individuals but they are unlikely to explain the large
differences observed. Similarly, our analysis cannot distinguish
patient or doctor initiated prescribing. It is plausible that
prescribing of anxiolytic medication may be requested by bereaved
individuals or their relatives and this needs to be considered in
interpreting the policy and clinical implications of our findings.
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Our results will be influenced by loss to follow up due to death
and deregistration. This is partially addressed by our use of
censored analysis and comparison with a matched control group
but this cannot account for informative loss to follow up. However,
for these loses to introduce bias would require a complex
interaction between bereavement, the likelihood of receiving
psychotropic medication and loss to follow up which we feel is
unlikely.
Context
We are only aware of one recent large study which has
examined psychotropic prescribing in unselected bereaved indi-
viduals. This Swedish study found modestly increased risks of
receiving any psychotropic medication in the year after bereave-
ment but did not further describe this effect by drug type or time
since bereavement [7]. A Danish study examined prescribing after
myocardial infarction and reported on monthly antidepressant and
Table 3. Adjusted Hazard Ratios for Predictors of Initiation of Anxiolytics/Hypnotics within 2 months of Bereavement.
Group Bereaved (n =21,122) Non-Bereaved* (n =59,280)
Total Initia-tors % HRa 95% CI HRa Interaction Testb
Gender P = 0.75
Men 8,186 596 7.3% 1 _ 1
Women 12,936 1,148 8.9% 1.18 1.07 to 1.31 1.41
Age at bereavement P,0.001
60–64 1,279 133 10.4% 1.24 1.01 to 1.50 1.08
65–69 3,269 325 9.9% 1.15 1.00 to 1.34 0.87
70–74 4,390 372 8.5% 0.99 0.87 to 1.14 0.68
75–79 5,004 426 8.5% 1 _ 1
80–84 4,410 327 7.4% 0.89 0.77 to 1.03 0.93
85+ 2,770 161 5.8% 0.70 0.59 to 0.84 1.24
Townsend Quintile (Deprivation) P = 0.98
1 (Least Deprived) 5,859 474 8.1% 1 _ 1
2 5,338 436 8.2% 0.99 0.87 to 1.13 1.10
3 4,316 331 7.7% 0.92 0.80 to 1.06 1.02
4 3,406 300 8.8% 1.05 0.91 to 1.22 1.19
5 (Most Deprived) 1,777 167 9.4% 1.09 0.91 to 1.30 1.27
Missing 426 36 8.5% 0.98 0.70 to 1.38 0.85
Charlson Index (Comorbidity) P,0.001
0 10,279 844 8.2% 1 _ 1
1 5,114 443 8.7% 1.09 0.97 to 1.22 1.26
2–3 4,461 379 8.2% 1.07 0.94 to 1.21 1.27
4+ 1,088 78 7.2% 0.96 0.76 to 1.22 2.59
Depression P = 0.77
No History 19,559 1,545 7.9% 1 _ 1
History 1,563 199 12.7% 1.60 1.38 to 1.86 1.52
Bereavement Expectation n/a
Unexpected 2,805 251 9.0% 1.15 1.01 to 1.32 _
Known Partner Comorbidity 18,317 1,493 8.2% 1 _ _
Bereavement Season P = 0.38
Non-Winter 13,676 1,094 8.0% 1 _ 1
Winter 7,446 650 8.7% 1.11 1.01 to 1.22 0.99
Practice Anx/Hyp PrescribingC P = 0.80
I (0 to 5.86%) 4,009 248 6.2% 1 _ 1
II (5.86 to 7.09%) 4,595 365 7.9% 1.29 1.09 to 1.52 1.10
III (7.09 to 8.31%) 4,327 324 7.5% 1.22 1.03 to 1.45 1.10
IV (8.31 to 10.49%) 4,885 436 8.9% 1.49 1.27 to 1.75 1.35
V (10.49 and above) 3,306 371 11.2% 1.70 1.43 to 2.03 1.89
aHazard ratios adjusted for all determinants in table, UK Region and Year.
bComparing Association in Bereaved and Non-Bereaved Groups.
cQuintiles of annual practice prescribing to non-bereaved couples (% of patients in receipt of this drug class).
*Full data on non-bereaved analysis is presented in table S1.
doi:10.1371/journal.pone.0077734.t003
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benzodiazepine prescribing after bereavement with a similar
pattern to our study [8].
Implications
Anxiolytic and Hypnotics. Our study confirms that prescrib-
ing of anxiolytics/hypnotics is common after bereavement. In
absolute terms, there is a 9.3% higher risk of receiving these drugs in
the year after bereavement (derived from figure 2). Their short-term
use is not contra-indicated and pharmacological relief of distress or
insomnia may be viewed as a compassionate clinical response
[5,13]. However, there is a concern that use of these drugs may
inhibit normal grieving. A small RCT, with benzodiazepines, did
not find that their use altered the psychological response to
bereavement but reported prolonged sleep disturbance [5].
Evidence from studies on post-traumatic stress disorder also raise
Table 4. Adjusted Hazard Ratios for Predictors of Initiation of Antidepressants within 6 months of Bereavement.
Group Bereaved (n =21,122) Non-Bereaved* (n=59,280)
Total Initia-tors % HRa 95% CI HRa Interaction Testb
Gender P = 0.13
Men 8,186 336 4.1% 1 _ 1
Women 12,936 660 5.1% 1.30 1.13 to 1.48 1.62
Age at bereavement P,0.001
60–64 1,279 79 6.2% 1.30 1.01 to 1.69 0.73
65–69 3,269 155 4.7% 0.98 0.80 to 1.20 0.77
70–74 4,390 181 4.1% 0.85 0.70 to 1.03 0.77
75–79 5,004 243 4.9% 1 _ 1
80–84 4,410 192 4.4% 0.91 0.75 to 1.10 1.24
85+ 2,770 146 5.3% 1.14 0.93 to 1.40 1.59
Townsend Quintile (Deprivation) P = 0.003
1 (Least Deprived) 5,859 242 4.1% 1 _ 1
2 5,338 253 4.7% 1.15 0.97 to 1.38 1.32
3 4,316 183 4.2% 1.03 0.85 to 1.24 1.50
4 3,406 196 5.8% 1.38 1.14 to 1.68 1.03
5 (Most Deprived) 1,777 107 6.0% 1.39 1.10 to 1.76 1.86
Missing 426 15 3.5% 0.86 0.51 to 1.45 0.74
Charlson Index (Comorbidity) P = 0.50
0 10,279 426 4.1% 1 _ 1
1 5,114 238 4.7% 1.13 0.96 to 1.33 1.22
2–3 4,641 255 5.5% 1.38 1.18 to 1.62 1.46
4+ 1,088 77 7.1% 1.85 1.45 to 2.37 2.04
Depression P = 0.37
No History 19,559 870 4.5% 1 _ 1
History 1,563 126 8.1% 1.75 1.45 to 2.11 2.04
Bereavement Expectation n/a
Unexpected 2,805 137 4.9% 1.10 0.92 to 1.32 _
Known Partner Comorbidity 18,317 859 4.7% 1 _ _
Bereavement Season P = 0.80
Non-Winter 13,676 627 4.6% 1 _ 1
Winter 7,446 369 5.0% 1.03 0.90 to 1.17 1.02
Practice Antidepresant Prescribingc P = 0.58
I (0 to 6.56%) 3,647 132 3.6% 1 _ 1
II (6.56 to 7.88%) 5,192 237 4.6% 1.29 1.04 to 1.60 1.12
III (7.88 to 9.00%) 4,684 224 4.8% 1.35 1.09 to 1.68 1.49
IV (9.00 to 10.66%) 4,429 224 5.1% 1.41 1.13 to 1.76 1.41
V (10.66 and above) 3,170 179 5.7% 1.60 1.25 to 2.04 1.52
aHazard ratios adjusted for all determinants in table, UK Region and Year.
bComparing Association in Bereaved and Non-Bereaved Groups.
cQuintiles of annual practice prescribing to non-bereaved couples (% of patients in receipt of this drug class).
*Full data on non-bereaved analysis is presented in table S1.
doi:10.1371/journal.pone.0077734.t004
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concerns over the long terms effects of benzodiazepines used to
manage initial distress after traumatic events [18].
Our findings raise other concerns. The high continuation rate of
these drugs is counter to current guidelines, which only support
short-term use to minimise the well-established harm from long-
term use [19,20]. Initiation after bereavement may be an
important gateway to long-term use and dependency [6]. In our
analysis, at least one in eight patients continued medication at one
year with a risk of continuation similar to prescribing outside the
bereavement period. This risk needs to be considered in
determining the benefit to harm ratio for prescribing after a
common event during the life course of older people.
A further concern from our study is the large practice variation,
which is not explained by differences in deprivation or patient
comorbidity, and apparently determined by clinician prescribing
propensity. Such variation suggests that prescribing indications are
far from consistent and that prescribing habit, rather than
individual circumstances, determine whether an individual
receives medication after bereavement.
Antidepressants. In absolute terms, the effect of bereave-
ment on antidepressant prescribing is relatively modest, with a
1.4% increased risk in the first two months and 5.5% in the first
year (derived from figure 2), but our findings gives an important
insight into clinical practice after bereavement and current
adherence to the bereavement exclusion. The risk of antidepres-
sant prescribing was greatest in the first two months after
bereavement and decreased slightly by six months and markedly
by one year which suggests that the previous bereavement
exclusion had little effect on clinician decision making. A
reluctance to diagnose, and pharmacologically treat, depression
in the first two months after bereavement, limiting treatment to
those with severe symptoms, would delay the increase in
prescribing and see a marked increase after two months. This
means, at least in the UK, removal of the bereavement exclusion
from criteria for diagnosis of major depressive episodes may not be
helpful and potentially promote excessive prescribing. The main
driver for this change is a desire not to withhold effective treatment
after bereavement [4]. As the previous bereavement exclusion was
not measurably reducing or delaying prescribing, this recent
change to the diagnostic criteria may lead to excessive treatment if
diagnostic specificity is poorer in primary care, where it may be
more difficult to distinguish between normal grief and depression.
It is important that any change to diagnostic criteria, which
further encourage prescribing, are supported by an evidence base
on the effectiveness and harm from treatment to allow informed
decisions by patients and clinicians. The current evidence on
antidepressants for early bereavement related depression is limited,
but does suggest that treatment may relieve depression symptoms
but not manifestations of grief [3,21,22]. This limited evidence
base stresses the importance of distinguishing grief from depres-
sion. In addition, some authors suggest that depression after
bereavement is qualitatively and prognostically different from
depression at other points in the life course which raises
uncertainty over the need for treatment [23].
A central argument for removing the depression exclusion in
DSM-5 was that bereavement related depression is not meaning-
fully different from other major depressive episodes and hence
exclusion has no scientific or clinical basis [4,24]. The similarity of
most predictors of prescribing in bereaved and non-bereaved
individuals, in particular previous history of depression and
comorbidity, is reassuring. However, the marked difference in
the effect of age raises some concern that prescribing may indicate
treatment of grief rather than depression. It could be argued that
depression is known to be under-diagnosed in older people and the
increased recognition after bereavement may be helpful in
addressing this concern. However, the potential for misclassifica-
tion of patients with grief and depression may mean such increased
recognition is counter-productive and not necessarily benefical.
Although our study cannot comment directly on use of non-
drug psychological therapies, there may be a role for such therapy
in line with stepped care guidance for depression, in bereaved
individuals in place of antidepressant therapy or as preventive
therapy [25].
The common use of psychotropic medication after bereavement
raises concerns over social and cultural iatrogenesis with medica-
tion viewed by patients, clinicians, families and society as an easy,
and potentially cheaper, substitute for social or psychological
support and professional time [26]. Society and health services
need to consider whether current medication initiation rates are
desirable and whether there are better ways to respond to the
needs and distress of bereaved individuals.
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